Quarterly report pursuant to Section 13 or 15(d)

SCHEDULE OF IDENTIFIABLE INTANGIBLE ASSETS CARRYING VALUE (Details)

v3.22.2.2
SCHEDULE OF IDENTIFIABLE INTANGIBLE ASSETS CARRYING VALUE (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]    
Total $ 31,951 $ 31,951
Accumulated Amortization (30,772) (29,819)
Net Carrying Value 1,179 2,132
CLIA Lab [Member]    
Finite-Lived Intangible Assets [Line Items]    
Total $ 609 609
Finite lived intangible asset, useful life 2 years 3 months 18 days  
Asuragen Acquisition [Member] | Thyroid [Member]    
Finite-Lived Intangible Assets [Line Items]    
Total $ 8,519 8,519
Finite lived intangible asset, useful life 9 years  
Red Path Acquisition [Member] | Pancreas Test [Member]    
Finite-Lived Intangible Assets [Line Items]    
Total $ 16,141 16,141
Finite lived intangible asset, useful life 7 years  
Red Path Acquisition [Member] | Barretts Test [Member]    
Finite-Lived Intangible Assets [Line Items]    
Total $ 6,682 $ 6,682
Finite lived intangible asset, useful life 9 years